Akorn Inc.


Stock Update (NASDAQ:AKRX): Akorn, Inc. Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection

Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched Buprenorphine and Naloxone Sublingual Tablets CIII in 2mg/0.

Company Update (NASDAQ:AKRX): Akorn, Inc. Provides Business and Financial Guidance Update

Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, today provided an update on the company’s ongoing restatement process as well as a business …

Stock Update (NASDAQ:AKRX): Akorn, Inc. Appoints Duane A. Portwood as Chief Financial Officer

Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, today announced that Duane A.

Stock Update (NASDAQ:AKRX): Akorn, Inc. Launches Two Additional Promethazine Syrup Formulations

Akorn, Inc. (NASDAQ:AKRX), a leading specialty pharmaceutical company, today announced that it has launched Promethazine Hydrochloride and Phenylephrine Hydrochloride Syrup (Promethazine/Phenylephrine) and Promethazine Hydrochloride, …

Stock Update (NASDAQ:AKRX): Akorn, Inc. Appoints Randy Pollard as Interim Chief Financial Officer

Akorn, Inc. (NASDAQ:AKRX) announced the appointment ofRandall Pollard as Chief Accounting Officer and Interim Chief Financial Officer.

William Blair Offers Commentary on Akorn, Inc. Following Earnings Restatement

Akorn, Inc. (NASDAQ:AKRX) dropped 22% yesterday after announcing the discovery of additional errors related to Hi-Tech products during the first-quarter accounting process, which will delay …

Analysts Disagree Over Significance of Akorn, Inc.’s Financial Errors (AKRX)

Akorn, Inc. (NASDAQ:AKRX) announced on Friday that it will have to restate financials from 2014 due to accounting errors.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts